VCEL
NasdaqVERICEL CORPORATION
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$156.2M
2021
$164.4M
2022
$197.5M
2023
$237.2M
2024
$276.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$276.3M
Net Income$16.5M
Gross Profit$205.6M
Oper Income$11.0M
EPS (dil)$0.32
Rev/sh$5.41
FCF/sh$0.48
Book/sh$6.94
Gross M74.4%
Oper M4.0%
Profit M6.0%
FCF M9.0%
ROE4.7%
ROA3.4%
ROIC3.9%
R&D/Rev10.0%
Rev Y/Y16.5%
Rev 3Y CAGR18.9%
EPS Y/Y60.0%
EPS 3Y CAGR—
FCF 3Y CAGR34.9%
Payout—
Div/sh—
Shs Chg Y/Y+0.9%
Current Ratio5.03
Quick Ratio4.68
Debt/Eq0.04
Int Coverage17.5×
Net Debt$86.9M cash
Total Debt$13.2M
Cash & Eq$100.1M
Total Assets$488.0M
Oper CF$51.9M
Capex$27.2M
Free CF$24.7M
Buybacks—
Equity$354.6M
Liabilities$133.3M
Shs Outstand0.05B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $156.2M | $164.4M | $197.5M | $237.2M | $276.3M |
| Gross Profit | $106.0M | $109.8M | $135.6M | $172.1M | $205.6M |
| Operating Income | $-7.9M | $-17.1M | $-6.5M | $4.5M | $11.0M |
| Net Income | $-7.5M | $-16.7M | $-3.2M | $10.4M | $16.5M |
| Diluted EPS | $-0.16 | $-0.35 | $-0.07 | $0.20 | $0.32 |
| Operating Cash Flow | $29.0M | $17.7M | $35.3M | $58.2M | $51.9M |
| Free Cash Flow | $21.1M | $10.1M | $15.3M | $-5.8M | $24.7M |
COMMUNITY · $VCEL0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.